Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 0.71 |
| ▸ | TP53 | P04637 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.71 |
| ▸ | THPO | P40225 | 2/20 | 0.71 |
| ▸ | GMNN | O75496 | 2/20 | 0.71 |
| ▸ | MTOR | P42345 | 2/20 | 0.71 |
| ▸ | BLM | P54132 | 2/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.71 |
| ▸ | PPM1B | O75688 | 1/20 | 0.71 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.71 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.71 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.71 |
| ▸ | PPP5C | P53041 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cantharidin SCHEMBL152261 | 0.84 | MAPK1 (1.00) | MAPK1TP53CYP3A4HIF1ALMNA | |
| Cantharidin SCHEMBL14120808 | 0.84 | MAPK1 (1.00) | MAPK1TP53CYP3A4HIF1ALMNA | |
| Cantharidin SCHEMBL1805181 | 0.84 | MAPK1 (1.00) | MAPK1TP53CYP3A4HIF1ALMNA | |
| Cantharidin SCHEMBL152262 | 0.84 | MAPK1 (1.00) | MAPK1TP53CYP3A4HIF1ALMNA | |
| SCHEMBL24129015 | 0.71 | MAPK1 (0.67) | MAPK1TP53CYP3A4HIF1ALMNA | |
| SCHEMBL19619602 | 0.71 | MAPK1 (0.67) | MAPK1TP53CYP3A4HIF1ALMNA | |
| SCHEMBL22369623 | 0.69 | TP53 (0.44) | MAPK1TP53CYP3A4HIF1ALMNA | |
| SCHEMBL20618517 | 0.69 | MAPK1 (0.62) | MAPK1TP53CYP3A4HIF1ALMNA | |
| SCHEMBL23080410 | 0.66 | TP53 (0.57) | MAPK1TP53CYP3A4HIF1ALMNA | |
| SCHEMBL3496407 | 0.66 | MAPK1 (0.59) | MAPK1TP53CYP3A4HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3692044-B1 | SYNTHESIS OF CANTHARIDIN | VERRICA PHARMACEUTICALS INC (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20200270269-A1 | SYNTHESIS OF CANTHARIDIN | VERRICA PHARMACEUTICALS, INC. (US) | 2020-08-27 | — | — | US | disclosed |
| WO-2019070980-A2 | SYNTHESIS OF CANTHARIDIN | VERRICA PHARMACEUTICALS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270269-A1 | SYNTHESIS OF CANTHARIDIN | TYR, NQO1, CBR3 | MAPK1 1224/4885TP53 3593/4885CYP3A4 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.